Effect of probiotic and prebiotic on psychological outcomes in patients with major depressive disorder: A randomized clinical trial

Kurosh Djafarian¹, Asma Kazemi¹, Ahmad Ali Noorbala²

¹Department of clinical nutrition, School of Nutritional Sciences and Dietetic, Tehran University of Medical Sciences, Tehran, Iran; ²Psychosomatic Medicine Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran;

Background: Major depressive disorders have been associated with potential psychological outcomes, but there are few data on the effects of probiotics and prebiotics on these outcomes.

Objective: The aim of this double blind, placebo-control trial, was to investigate the effect of prebiotic and probiotic on serum inflammatory cytokines (TNF- α , IL-1 β , IL-6 and IL-10), Beck Depression Inventory (BDI) score, serum kynurenine/tryptophan ratio and tryptophan/BCAAs ratio, BMI, and urinary cortisol in patients with major depressive disorder (MDD).

Design: One hundred and ten depressed patients were randomized to receive the probiotic (Lactobacillus helveticus and Bifidobacterium longum), prebiotic (galactooligosaccharide) or placebo for 8 weeks. BDI score was determined by means of a self-compiled questionnaire. Serum tryptophan and BCAAs were measured by HPLC, kynurenine and leptin by ELISA kits and urinary cortisol via chemiluminescence.

Results: A total of 81 subjects completed the trial (28 in the probiotic group, 27 in the prebiotic group, and 26 in the placebo group). Patients in probiotic group resulted in a significant decrease in BDI score (17.39 ± 9.1) compared to the placebo (18.18 ± 15.55) and prebiotic (19.72 ± 14.14).

Inter-group comparison indicated no significant differences among the groups in terms of serum kynurenine/tryptophan ratio and tryptophan/BCAAs ratio. However, the kynurenine/tryptophan ratio decreased in the probiotic compared to the placebo group (0.036) and the tryptophan/BCAAs ratio decreased in the prebiotic compared to the placebo group (0.031). Moreover, the tryptophan/isoleucine ratio increased significantly in the probiotic (p=0.018) and prebiotic (0.025) group when compared to the placebo. No significant difference in both BMI and weight was seen among the groups.

Conclusion: This study confirmed that probiotic supplements for 8 weeks among MDD patients resulted in an improvement in BDI score whereas prebiotic administration had no significant effect on BDI score. Probiotic decreased serum kynurenine/tryptophan ratio while prebiotic decreased serum tryptophan/BCAAs ratio. Supplementations had no significant effects in modulating inflammatory marker levels and urinary cortisol in MDD patients.

Key words: probiotic, prebiotic, major depressive disorders.